Learn how to order either FLEXBUMIN 25% [Albumin (Human)], 25% Solution or BUMINATE today.
More >
Resources
Baxter is committed to providing you with useful tools delivering clinical information about human albumin therapies. We hope the resources below will be helpful and answer questions you might have about albumin therapy or our offerings in the field.
Albumin Slide Kit
Our Albumin Slide Kit can be used for personal reference or professional presentation. Topics covered include:
- Albumin pharmacology
- Physiological roles of albumin
- Effect of albumin on intravascular volume
- Indications for albumin
Information Sheet for FLEXBUMIN 25% [Albumin (Human)], 25% Solution
FLEXBUMIN is the first and only formulation of human albumin available in a flexible container.
Download the Information Sheet to learn more about FLEXBUMIN benefits and ordering information.
FLEXBUMIN 25% [Albumin (Human)]
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
Please see Important Risk Information for FLEXBUMIN 25% and Full Prescribing Information.
BUMINATE 5% [Albumin (Human)], USP, 5% Solution
BUMINATE 5% [Albumin (Human)], USP, 5% Solution is indicated for Hypovolemia, Hypoalbuminemia due to general causes and burns, and use during or prior to cardiopulmonary bypass surgery.
Please see Important Risk Information for BUMINATE 5% and Full Prescribing Information.
BUMINATE 25% [Albumin (Human)], USP, 25% Solution
Buminate 25% [Albumin (Human)], USP, 25% Solution is indicated for Hypovolemia, Hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, for use during or prior to cardiopulmonary bypass surgery, and Hemolytic disease of the newborn (HDN).
Please see Important Risk Information for BUMINATE 25% and Full Prescribing Information.
